Effects of Alendronate Sodium and Vitamin D3 on T Cell Immune Indexes in Patients with Different Genders and Ages with Advanced Lung Cancer
10.6039/j.issn.1001-0408.2016.26.16
- VernacularTitle:阿仑膦酸钠维D3对不同性别、年龄晚期肺癌患者T细胞免疫指标的影响Δ
- Author:
Xiaoying LI
;
Qichao XIE
- Publication Type:Journal Article
- Keywords:
Advanced lung cancer;
Vitamin D;
T cell;
Treg;
Gender;
Age
- From:
China Pharmacy
2016;27(26):3652-3654,3655
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effect of alendronte sodium and vitamin D3 on the T cell immune indexes in patients with different genders and ages with advanced lung cancer. METHODS:76 patients with advanced lung cancer were divided into non-small cell lung cancer(NSCLC)group(n=40)and small cell lung cancer(SCLC)group(n=36),and another 38 healthy vol-unteers were control group. Based on palliative care,all patients received Alendronte sodium and vitamin D3 tablet 1 tablet,po,qd, for 1 month. T cell immune indexes(CD4+,CD8+and Treg levels)in 2 groups before and after treatment,and when volunteers enroll-ing the control group were compared;and the incidence of adverse reactions were observed. RESULTS:Compared with control group,there were significant differences in CD4+,CD8+,CD4+/CD8+and Treg levels(P<0.05);but there was no significant differ-ence between NSCLC group and SCLC group(P>0.05). After treatment,CD4+ and CD4+/CD8+ levels in NSCLC group and SCLC group increased,changes of male were greater than female,CD8+and Treg levels decreased,changes of male were greater than fe-male,except for CD8+ level in NSCLC group (P=0.33),there were significant differences in others (P<0.05);CD4+ and CD4+/CD8+ levels in patients ≤50 years old increased more than patients >50 years old,CD8+ and Treg levels decreased more than pa-tients >50 years old,the differences were statistically significant (P<0.05). No obvious adverse reactions were found. CONCLU-SIONS:Alendronte sodium and vitamin D3 can effectively improve the T cell immune indexes in patients with advanced lung cancer, especially for male and patients≤50 years old,which can be considered as conventional adjuvant drugs for patients with lung cancer.
